论文部分内容阅读
20世纪70年代末,药物专家根据人体胆固醇生物合成的机制,开始筛选胆固醇合成限速酶———3羟3甲基戊二酸单酰辅酶A(hydroxy methylglutaryl co-enzyme A reductase inhibitor,HMG-CoA)还原酶抑制剂。经过十多年的努力,1987年,第一个他汀品种上市并获美国国家食品药品监督管理局(Food and Drug Administration,FDA)批准。自此,他汀药物临床应用的益处逐步被人们所认知。他汀类药物可以竞
In the late 1970s, according to the mechanism of human cholesterol biosynthesis, drug experts began to screen the cholesterol-synthesizing rate-limiting enzyme --- hydroxy methylglutaryl co-enzyme A reductase inhibitor (HMG- CoA) reductase inhibitor. After more than a decade of hard work, the first statin was listed in 1987 and approved by the Food and Drug Administration (FDA). Since then, the benefits of clinical use of statins have been gradually recognized. Statins can compete